Cargando…

Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor–Positive Primary Human Breast Tumors

Mostrar otras versiones (1)

PURPOSE: In estrogen receptor–positive (ER(+))/HER2(−) breast cancer, multiple measures of intratumor heterogeneity are associated with a worse response to endocrine therapy. We sought to develop a novel experimental model to measure heterogeneity in response to tamoxifen treatment in primary breast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyunsoo, Whitman, Austin A., Wisniewska, Kamila, Kakati, Rasha T., Garcia-Recio, Susana, Calhoun, Benjamin C., Franco, Hector L., Perou, Charles M., Spanheimer, Philip M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Translational Cancer Mechanisms and Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690085/ https://www.ncbi.nlm.nih.gov/pubmed/37747807 http://dx.doi.org/10.1158/1078-0432.CCR-23-1248

Ejemplares similares

Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors
por: Kim, Hyunsoo, et al.
Publicado: (2023)

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer
por: Xia, Youli, et al.
Publicado: (2022)

Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study
por: Bartlett, John M.S., et al.
Publicado: (2022)

Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor– and ErbB2-positive Breast Cancer
por: Viganò, Lucia, et al.
Publicado: (2022)

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
por: Bergamino, Milana A., et al.
Publicado: (2022)

Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer
por: Singer, Christian F., et al.
Publicado: (2022)

Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer
por: Sheehan, Beshara, et al.
Publicado: (2022)

A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
por: El Zawily, Amr, et al.
Publicado: (2023)

Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
por: Cornwell, Abigail C., et al.
Publicado: (2023)

Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
por: Fernández-Miranda, Ismael, et al.
Publicado: (2023)

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
por: Serra-Camprubí, Queralt, et al.
Publicado: (2023)

Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
por: Eisner, Joel R., et al.
Publicado: (2023)

Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma
por: Berger, Barry M., et al.
Publicado: (2022)

Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance
por: Hanna, Glenn J., et al.
Publicado: (2023)

Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors
por: Nash, Amanda M., et al.
Publicado: (2022)

Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
por: Nakamura, Kyoko, et al.
Publicado: (2021)

Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
por: Rodriguez-Berriguete, Gonzalo, et al.
Publicado: (2023)

Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA
por: Neumayer, Christoph, et al.
Publicado: (2023)

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy
por: Bai, Xue, et al.
Publicado: (2021)

Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
por: Sperger, Jamie M., et al.
Publicado: (2023)

Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
por: Johannet, Paul, et al.
Publicado: (2022)

A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
por: Ramos, Louise, et al.
Publicado: (2023)

ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis
por: Tew, Ben Yi, et al.
Publicado: (2023)

Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer
por: Carter, Jodi M., et al.
Publicado: (2021)

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
por: Batalini, Felipe, et al.
Publicado: (2022)

TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer
por: Heiduk, Max, et al.
Publicado: (2023)

Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer
por: Durinikova, Erika, et al.
Publicado: (2022)

Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
por: Coleman, Ilsa M., et al.
Publicado: (2022)

The TAZ-CAMTA1 Fusion Protein Promotes Tumorigenesis via Connective Tissue Growth Factor and Ras–MAPK Signaling in Epithelioid Hemangioendothelioma
por: Ma, Shuang, et al.
Publicado: (2022)

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
por: Kim, Dae-Hwan, et al.
Publicado: (2021)

Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes
por: Bolton, Kelly L., et al.
Publicado: (2022)

Spatial and Transcriptomic Analysis of Perineural Invasion in Oral Cancer
por: Schmitd, Ligia B., et al.
Publicado: (2022)

Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer
por: Leto, Simonetta M., et al.
Publicado: (2023)

A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration-Resistant Prostate Cancer
por: Dylgjeri, Emanuela, et al.
Publicado: (2022)

Neoantigen Targetability in Progressive Advanced Melanoma
por: van den Bulk, Jitske, et al.
Publicado: (2023)

Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia
por: Ding, Yang-Yang, et al.
Publicado: (2021)

DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks
por: Venugopal, Kartika, et al.
Publicado: (2022)

Ovarian Cancer–Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial
por: Schouten, Philip C., et al.
Publicado: (2021)

Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial
por: Lynggaard, Charlotte Duch, et al.
Publicado: (2022)

Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma
por: Nunes, Raquel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n4tbq9nd27v675i7o2rsaegef7